CYP2A7 explained

CYP2A7 (cytochrome P450, family 2, subfamily A, polypeptide 7) is a protein that in humans is encoded by the CYP2A7 gene.^{[1] [2]}

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum; its substrate has not yet been determined. This gene, which produces two transcript variants, is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.

Further reading

• Smith BD, Sanders JL, Porubsky PR . Structure of the human lung cytochrome P450 2A13 . J. Biol. Chem. . 282 . 23 . 17306–13 . 2007 . 17428784 . 10.1074/jbc.M702361200 . etal. free .
• Wang HH, Liao YW, Chiang HL . Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population . Pharmacogenomics . 10 . 3 . 359–74 . 2009 . 19290787 . 10.2217/14622416.10.3.359 . etal.
• Fernandez-Salguero P, Gonzalez FJ . The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis . Pharmacogenetics . 5 . Special Issue . S123–8 . 1995 . 7581481 . 10.1097/00008571-199512001-00013.
• Cauffiez C, Lo-Guidice JM, Quaranta S . Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility . Biochem. Biophys. Res. Commun. . 317 . 2 . 662–9 . 2004 . 15063809 . 10.1016/j.bbrc.2004.03.092 . etal.
• Timofeeva MN, Kropp S, Sauter W . CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences . Carcinogenesis . 30 . 7 . 1161–9 . 2009 . 19414505 . 10.1093/carcin/bgp102 . etal. free .
• Smith G, Stubbins MJ, Harries LW, Wolf CR . Molecular genetics of the human cytochrome P450 monooxygenase superfamily . Xenobiotica . 28 . 12 . 1129–65 . 1998 . 9890157 . 10.1080/004982598238868 .
• Saito A, Kawamoto M, Kamatani N . Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects . J. Hum. Genet. . 54 . 6 . 317–23 . 2009 . 19343046 . 10.1038/jhg.2009.31 . free .
• He XY, Shen J, Ding X . Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen . Drug Metab. Dispos. . 32 . 12 . 1516–21 . 2004 . 15333516 . 10.1124/dmd.104.001370 . 26225467 . etal.
• Nelson DR, Zeldin DC, Hoffman SM . Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants . Pharmacogenetics . 14 . 1 . 1–18 . 2004 . 15128046 . 10.1097/00008571-200401000-00001 . etal.
• He XY, Shen J, Hu WY . Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation . Arch. Biochem. Biophys. . 427 . 2 . 143–53 . 2004 . 15196988 . 10.1016/j.abb.2004.03.016 . etal.
• Herr D, Bettendorf H, Denschlag D . Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma . Arch. Gynecol. Obstet. . 274 . 6 . 367–71 . 2006 . 16835796 . 10.1007/s00404-006-0201-8 . 28342598 . etal.
• Song DK, Xing DL, Zhang LR . Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China . Cancer Detect. Prev. . 32 . 5–6 . 416–23 . 2009 . 19303722 . 10.1016/j.cdp.2009.02.003 . etal.
• Fujieda M, Yamazaki H, Kiyotani K . Eighteen novel polymorphisms of the CYP2A13 gene in Japanese . Drug Metab. Pharmacokinet. . 18 . 1 . 86–90 . 2003 . 15618722 . 10.2133/dmpk.18.86 . etal.
• Wang H, Tan W, Hao B . Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK . Cancer Res. . 63 . 22 . 8057–61 . 2003 . 14633739 . etal.
• Cheng XY, Chen GL, Zhang WX . Arg257Cys polymorphism of CYP2A13 in a Chinese population . Clin. Chim. Acta . 343 . 1–2 . 213–6 . 2004 . 15115698 . 10.1016/j.cccn.2004.01.017 . etal.
• D'Agostino J, Zhang X, Wu H . Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidence of lung adenocarcinoma in smokers . Drug Metab. Dispos. . 36 . 11 . 2316–23 . 2008 . 18669584 . 10.1124/dmd.108.022822 . 2597635 . etal.
• Cauffiez C, Pottier N, Tournel G . CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations . Xenobiotica . 35 . 7 . 661–9 . 2005 . 16316926 . 10.1080/00498250500202171 . 39901230 . etal.
• Mohelnikova-Duchonova B, Vrana D, Holcatova I . CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk . Pancreas . 39 . 2 . 144–8 . 2010 . 19812523 . 10.1097/MPA.0b013e3181bab6c2 . 25113289 . etal.
• Jiang JH, Jia WH, Chen HK . Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population . J Transl Med . 2 . 1 . 24 . 2004 . 15222883 . 10.1186/1479-5876-2-24 . 455696 . etal . free .
• Young RP, Hopkins RJ, Hay BA . A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers . Postgrad Med J . 85 . 1008 . 515–24 . 2009 . 19789190 . 10.1136/pgmj.2008.077107 . etal. free .

Notes and References

1. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR . A Genetic Polymorphism in Coumarin 7-Hydroxylation: Sequence of the Human CYP2A Gnes and Identification of Variant CYP2A6 Alleles . Am. J. Hum. Genet. . 57 . 3 . 651–60 . September 1995 . 7668294 . 1801261 .
2. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW . Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants . Pharmacogenetics . 14 . 1 . 1–18 . January 2004 . 15128046 . 10.1097/00008571-200401000-00001.